FUTURE PLAN

The following actions are to be undertaken for future prospects.

- Sub-acute toxicity, *In vivo* bio-availability studies to prove oral absorption.
- Efficacy study of SV7 in HT-29 colon cell line and MCF-7 breast cell line induced carcinogenesis in xenograft (nude mice) model.
- Claiming for complete specification after one year of provisional registration of patent (in Feb 2016).
- Exploring the additional potent leads for effectiveness against cancer ailment.